瓦尔内瓦疫苗

While Valneva SE may seem inexpensive after its substantial price decline over the past year, we've limited its rating to 3 stars to account for the possibility that it may represent a value trap. The stock currently trades at a 50% discount to our quantitative fair value estimate of $11.71 per share; however, caution is warranted due to this estimate's very high uncertainty rating.

The firm's balance sheet increases our quantitative valuation. Leverage can enable a company to invest in growth, potentially boosting shareholder value more than equity financing alone. Reflecting the firm's leverage is its EBITDA/interest coverage ratio of -2.9, which lies in the bottom 20% compared with peers globally. Although the firm's ability to cover interest payments with EBITDA is limited, shares could sharply rebound if economic circumstances change or recent investments reduce fears of default. We believe this is a sign that shares could be cheap.

On a different note, the company's valuation metrics are potentially concerning. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. The firm's enterprise value to revenue ratio of 4.0, for example, sits in the top 40% compared with peers globally. This overstates the long-term cash flow growth potential of the organization. Despite our favorable price/fair value ratio, this characteristic is a negative attribute.

With its quantitative economic moat rating of none, we do not expect this company to materially outearn its cost of capital in the long run. Additionally, the firm's moderate financial health score suggests it is acceptably positioned against adverse economic circumstances.